Efficacy of Daromun Neoadjuvant Intratumoral Treatment in Clinical Stage IIIB/C/D Melanoma Patients (NCT03567889)
An Open-Label, Randomized, Controlled Multi-Center Study of The Efficacy of Daromun (L19IL2 + L19TNF) Neoadjuvant Intratumoral Treatment Followed by Surgery and Adjuvant Therapy Versus Surgery and Adjuvant Therapy in Clinical Stage IIIB/C/D Melanoma Patients
🩺 Plain-English Summary (8th-Grade Level)
The trial aims to evaluate the efficacy of Daromun neoadjuvant treatment followed by surgery and adjuvant therapy to improve in a statistically significant manner the recurrence-free survival (RFS) of Stage IIIB/C/D melanoma patients with respect to the standard of care (surgery and adjuvant therapy).
Who can join: Review the eligibility criteria below.
Location: Mayo Clinic Hospital — Phoenix, Arizona
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (37 Sites)
Showing the first 25 of 37 sites.
- Mayo Clinic Hospital — Phoenix, Arizona
- UC San Diego Moores Cancer Center — La Jolla, California
- UC Irvine Health-Chao Family Comprehensive Cancer Center — Orange, California
- Moffitt Cancer Center — Tampa, Florida
- Winship Cancer Institute, Emory university — Atlanta, Georgia
- Rush University Medical Center — Chicago, Illinois
- University of Iowa Hospitals and Clinics — Iowa City, Iowa
- Mayo Clinic — Rochester, Minnesota
- Rutgers Cancer Institute, 195 Little Albany Street — New Brunswick, New Jersey
- Ambulatory Care Center at NYC Langarone Health — New York, New York
- Memorial Sloan Kettering Cancer Center - Main Campus — Ney York, New York
- Duke University Medical Center - Duke Cancer Center — Durham, North Carolina
- Ohio State University Wexner Medical Center — Columbus, Ohio
- St. Luke's Cancer Center, Clinical Trial, 3rd floor, 1600 St. Luke's Blvd. — Easton, Pennsylvania
- Penn State Cancer Institute — Hershey, Pennsylvania
- Fox Chase Cancer Center 333 Cottman Avenue — Philadelphia, Pennsylvania
- The University of Texas M.D. Anderson Cancer Center — Houston, Texas
- Huntsman Cancer Institute, University of Utah 2000 Circle of Hope — Salt Lake City, UT, Utah
- VCU - McGlothlin Medical Education Center — Richmond, Virginia
- Hospital Universitari Germans Trias i Pujol — Badalona, Barcelona
- Hospital de la Santa Creu i Sant Pau — Barcelona, Barcelona
- Fir Huvh Fundacio Institut De Recerca Hospital Universitari Vall De Hebron — Barcelona, Barcelona
- Hospital Clinic Barcelona — Barcelona, Barcelona
- El Hospital Universitario De Gran Canaria Dr. Negrin — Las Palmas de Gran Canaria, Canarie
- Fundacion Onkologikoa Fundazioa — Donostia / San Sebastian, Gipuzkoa
📞 Contact the Study Coordinator
Phone: +41 (0) 43 544 88 02
Email: sheila.dakhel@philogen.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
Explore by condition: All Melanoma Stage IIIB clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.